Evidence map›Paper›PMID 36641615›Full record

ArticleThe journal of prevention of Alzheimer's disease2023

Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease.

K K Petersen, A Ezzati, R B Lipton, B A Gordon, J Hassenstab, J C Morris, E Grober

Abstract read
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Beneficial Effect of Societal Factors on APOE-ε2 and ε4 Carriers' Brain Health: A Systematic Review.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

K K PetersenKellen K. Petersen, Albert Einstein College of Medicine, 1225 Morris Park Avenue, Bronx, NY 10461, USA, kellen.petersen@einsteinmed.edu.
A Ezzati
R B Lipton
B A Gordon
J Hassenstab
J C Morris
E Grober

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7M
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI CHRISTOPHER G ENGELAND · 1985 to 2026
$73.9M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI Tammie Lee Smith Benzinger · 1985 to 2026
$69.5M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
MRI Measures of Cerebrovascular Injury and AD Atrophy in a Study of LatinosRF1AG054548 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DECARLI, CHARLES, GONZALEZ, HECTOR M · 2017 to 2017
$14.7M
A global epidemiology of cognitive impairment and dementia due to Alzheimer's disease and related disorders: the COSMIC CollaborationR01AG057531 · NIA · UNIVERSITY OF NEW SOUTH WALES · PI Perminder S SACHDEV · 2023 to 2026
$5.9M
Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA)R01AG048642 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GONZALEZ, HECTOR M · 2015 to 2019
$5.7M
Application of ambulatory methods for assessing short- and long-term associations of sleep health with cognitive decline in older adultsR01AG062622 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BUXTON, ORFEU M, DERBY, CAROL A. · 2019 to 2022
$3.1M
COSMIC: An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethno-racial groups and geographical settingsRF1AG057531 · NIA · UNIVERSITY OF NEW SOUTH WALES · PI SACHDEV, PERMINDER S · 2017 to 2020
$2.9M
FDA HHS UG3 FD006795NIA NIH HHS K01 AG053474NIA NIH HHS K23 AG063993NIA NIH HHS P01 AG003949NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS P50 AG005681NIA NIH HHS R01 AG048642NIA NIH HHS R01 AG057531NIA NIH HHS R01 AG060933NIA NIH HHS R01 AG062622NIA NIH HHS R21 AG056920NIA NIH HHS R56 AG057548NIA NIH HHS RF1 AG054548NIA NIH HHS RF1 AG057531NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG032438NINDS NIH HHS U10 NS077308NINDS NIH HHS U24 NS113847
6 · The paper itself

Abstract

objectiveTo investigate cerebrospinal fluid (CSF) and neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) based on Free and Cued Selective Reminding Test (FCSRT) performance, and to evaluate the effect of APOE ε4 status on this relationship.

methodsData from 586 cognitively unimpaired individuals who had FCSRT, CSF, and volumetric magnetic resonance imaging (MRI) measures available was used. We compared CSF measures of β-amyloid (Aβ42/Aβ40 ratio), phosphorylated tau (p-Tau181), total tau (t-Tau), hippocampal volume, and PIB-PET mean cortical binding potential with partial volume correction (MCBP) among SOMI groups in the whole sample and in subsamples stratified by APOE ε4 status.

resultsParticipants had a mean age of 67.4 (SD=9.1) years, had 16.1 (SD=2.6) years of education, 57.0% were female, and 33.8% were APOE ε4 positive. In the entire sample, there was no significant difference between SOMI stages in Aβ42/Aβ40 ratio, p-Tau181, t-Tau, or PIB-PET MCBP when adjusted for age, sex, and education. However, higher SOMI stages had smaller hippocampal volume (F=3.29, p=0.020). In the stratified sample based on APOE ε4 status, in APOE ε4 positive individuals, higher SOMI stages had higher p-Tau181 (F=2.94, p=0.034) higher t-Tau (F=3.41, p=0.019), and smaller hippocampal volume (F=5.78, p<0.001). There were no significant differences in CSF or imaging biomarkers between SOMI groups in the APOE ε4 negative subsample.

conclusionCognitively normal older individuals with higher SOMI stages have higher in-vivo tau and neurodegenerative pathology only in APOE ε4 carriers. These original results indicate the potential usefulness of the SOMI staging system in assessing of tau and neurodegenerative pathology.

Indexed as

Alzheimer DiseaseAgedAmyloid beta-PeptidesApolipoprotein E4BiomarkersFemaleHumansMaleMiddle AgedNeuroimagingAmyloid beta-PeptidesApolipoprotein E4BiomarkersAPOE ε4biomarkerscerebrospinal fluidcognitionSOMI

Identifiers

PMID36641615
PMCPMC9841119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.